|
1
|
Gazdar AF: Activating and resistance
mutations of EGFR in non-small-cell lung cancer: Role in clinical
response to EGFR tyrosine kinase inhibitors. Oncogene. 28(Suppl 1):
S24–S31. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roengvoraphoj M, Tsongalis GJ, Dragnev KH
and Rigas JR: Epidermal growth factor receptor tyrosine kinase
inhibitors as initial therapy for non-small cell lung cancer: Focus
on epidermal growth factor receptor mutation testing and
mutation-positive patients. Cancer Treat Rev. 39:839–850. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bose P and Ozer H: Neratinib: An oral,
irreversible dual EGFR/HER2 inhibitor for breast and non-small cell
lung cancer. Expert Opin Investig Drugs. 18:1735–1751. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li D, Ambrogio L, Shimamura T, Kubo S,
Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A,
Himmelsbach F, et al: BIBW2992, an irreversible EGFR/HER2 inhibitor
highly effective in preclinical lung cancer models. Oncogene.
27:4702–4711. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engelman JA, Zejnullahu K, Gale CM,
Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov
GN, Bradner JE, et al: PF00299804, an irreversible pan-ERBB
inhibitor, is effective in lung cancer models with EGFR and ERBB2
mutations that are resistant to gefitinib. Cancer Res.
67:11924–11932. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang J, Greulich H, Jänne PA, Sellers WR,
Meyerson M and Griffin JD: Epidermal growth factor-independent
transformation of Ba/F3 cells with cancer-derived epidermal growth
factor receptor mutants induces gefitinib-sensitive cell cycle
progression. Cancer Res. 65:8968–8974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Greulich H, Chen TH, Feng W, Jänne PA,
Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR,
et al: Oncogenic transformation by inhibitor-sensitive and
-resistant EGFR mutants. PLoS Med. 2:e3132005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mathew R, Karp CM, Beaudoin B, Vuong N,
Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, et al:
Autophagy suppresses tumorigenesis through elimination of p62.
Cell. 137:1062–1075. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh
H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, et al:
Promotion of tumorigenesis by heterozygous disruption of the beclin
1 autophagy gene. J Clin Invest. 112:1809–1820. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Turcotte S, Chan DA, Sutphin PD, Hay MP,
Denny WA and Giaccia AJ: A molecule targeting VHL-deficient renal
cell carcinoma that induces autophagy. Cancer Cell. 14:90–102.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fan XX, Li N, Wu JL, Zhou YL, He JX, Liu L
and Leung EL: Celastrol induces apoptosis in gefitinib-resistant
non-small cell lung cancer cells via caspases-dependent pathways
and Hsp90 client protein degradation. Molecules. 19:3508–3522.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wong VKW, Zhou H, Cheung SSF, Li T and Liu
L: Mechanistic study of saikosaponin-d (Ssd) on suppression of
murine T lymphocyte activation. J Cell Biochem. 107:303–315. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu MJ, Wang Z, Ju Y, Wong RNS and Wu QY:
Diosgenin induces cell cycle arrest and apoptosis in human leukemia
K562 cells with the disruption of Ca2+ homeostasis.
Cancer Chemother Pharmacol. 55:79–90. 2005. View Article : Google Scholar
|
|
16
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang WB, Feng LX, Yue QX, Wu WY, Guan SH,
Jiang BH, Yang M, Liu X and Guo DA: Paraptosis accompanied by
autophagy and apoptosis was induced by celastrol, a natural
compound with influence on proteasome, ER stress and Hsp90. J Cell
Physiol. 227:2196–2206. 2012. View Article : Google Scholar
|
|
18
|
Yang H, Chen D, Cui QC, Yuan X and Dou QP:
Celastrol, a triterpene extracted from the Chinese ‘Thunder of God
Vine’, is a potent proteasome inhibitor and suppresses human
prostate cancer growth in nude mice. Cancer Res. 66:4758–4765.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kannaiyan R, Shanmugam MK and Sethi G:
Molecular targets of celastrol derived from Thunder of God Vine:
Potential role in the treatment of inflammatory disorders and
cancer. Cancer Lett. 303:9–20. 2011. View Article : Google Scholar
|
|
20
|
Boridy S, Le PU, Petrecca K and Maysinger
D: Celastrol targets proteostasis and acts synergistically with a
heat-shock protein 90 inhibitor to kill human glioblastoma cells.
Cell Death Dis. 5:e12162014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng YN, Shi J, Liu J and Qu QM: Celastrol
protects human neuroblastoma SH-SY5Y cells from rotenone-induced
injury through induction of autophagy. Neurochem Int. 63:1–9. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoon MJ, Lee AR, Jeong SA, Kim YS, Kim JY,
Kwon YJ and Choi KS: Release of Ca2+ from the
endoplasmic reticulum and its subsequent influx into mitochondria
trigger celastrol-induced paraptosis in cancer cells. Oncotarget.
5:6816–6831. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li HY, Zhang J, Sun LL, Li BH, Gao HL, Xie
T, Zhang N and Ye ZM: Celastrol induces apoptosis and autophagy via
the ROS/JNK signaling pathway in human osteosarcoma cells: an in
vitro and in vivo study. Cell Death Dis. 6:e16042015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chan LY, Kosuri S and Endy D: Refactoring
bacteriophage T7. Mol Syst Biol. 1:00182005. View Article : Google Scholar
|
|
26
|
So KS, Kim CH, Rho JK, Kim SY, Choi YJ,
Song JS, Kim WS, Choi CM, Chun YJ and Lee JC:
Autophagosome-mediated EGFR down-regulation induced by the CK2
inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung
cancer cells with resistance by T790M. PLoS One. 9:e1140002014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
da Cunha Santos G, Shepherd FA and Tsao
MS: EGFR mutations and lung cancer. Annu Rev Pathol. 6:49–69. 2011.
View Article : Google Scholar
|
|
28
|
Pirker R and Filipits M: Cetuximab in
non-small-cell lung cancer. Transl Lung Cancer Res. 1:54–60.
2012.PubMed/NCBI
|
|
29
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al; West Japan Oncology Group. Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar
|
|
30
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al; Spanish Lung Cancer Group in
collaboration with Groupe Français de Pneumo-Cancérologie and
Associazione Italiana Oncologia Toracica. Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutation-positive non-small-cell lung cancer
(EURTAC): A multicentre, open-label, randomised phase 3 trial.
Lancet Oncol. 13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al; North-East Japan Study Group. Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan L and Beckman RA: Pharmacogenetics and
pharma-cogenomics in oncology therapeutic antibody development.
Biotechniques. 39(S10): 565–568. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pao W, Miller VA, Politi KA, Riely GJ,
Somwar R, Zakowski MF, Kris MG and Varmus H: Acquired resistance of
lung adenocarcinomas to gefitinib or erlotinib is associated with a
second mutation in the EGFR kinase domain. PLoS Med. 2:e732005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kohl NE, Conner MW, Gibbs JB, Graham SL,
Hartman GD and Oliff A: Development of inhibitors of protein
farnesylation as potential chemotherapeutic agents. J Cell Biochem
Suppl. 22(S22): 145–150. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ray D, Cuneo KC, Rehemtulla A, Lawrence TS
and Nyati MK: Inducing oncoprotein degradation to improve targeted
cancer therapy. Neoplasia. 17:697–703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vasan N, Boyer JL and Herbst RS: A RAS
renaissance: Emerging targeted therapies for KRAS-mutated non-small
cell lung cancer. Clin Cancer Res. 20:3921–3930. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hu H, Straub A, Tian Z, Bassler N, Cheng J
and Peter K: Celastrol, a triterpene extracted from Tripterygium
wilfordii Hook F, inhibits platelet activation. J Cardiovasc
Pharmacol. 54:240–245. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tang W and Zuo JP: Immunosuppressant
discovery from Tripterygium wilfordii Hook f: The novel triptolide
analog (5R)-5-hydroxytriptolide (LLDT-8). Acta Pharmacol Sin.
33:1112–1118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kannaiyan R, Manu KA, Chen L, Li F,
Rajendran P, Subramaniam A, Lam P, Kumar AP and Sethi G: Celastrol
inhibits tumor cell proliferation and promotes apoptosis through
the activation of c-Jun N-terminal kinase and suppression of PI3
K/Akt signaling pathways. Apoptosis. 16:1028–1041. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pankiv S, Clausen TH, Lamark T, Brech A,
Bruun JA, Outzen H, Øvervatn A, Bjørkøy G and Johansen T:
p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of
ubiquitinated protein aggregates by autophagy. J Biol Chem.
282:24131–24145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bjørkøy G, Lamark T, Brech A, Outzen H,
Perander M, Overvatn A, Stenmark H and Johansen T: p62/SQSTM1 forms
protein aggregates degraded by autophagy and has a protective
effect on huntingtin-induced cell death. J Cell Biol. 171:603–614.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ichimura Y, Kumanomidou T, Sou YS,
Mizushima T, Ezaki J, Ueno T, Kominami E, Yamane T, Tanaka K and
Komatsu M: Structural basis for sorting mechanism of p62 in
selective autophagy. J Biol Chem. 283:22847–22857. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Duran A, Linares JF, Galvez AS,
Wikenheiser K, Flores JM, Diaz-Meco MT and Moscat J: The signaling
adaptor p62 is an important NF-kappaB mediator in tumorigenesis.
Cancer Cell. 13:343–354. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Komatsu M, Waguri S, Koike M, Sou YS, Ueno
T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S, et al:
Homeostatic levels of p62 control cytoplasmic inclusion body
formation in autophagy-deficient mice. Cell. 131:1149–1163. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Takamura A, Komatsu M, Hara T, Sakamoto A,
Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K and Mizushima N:
Autophagy-deficient mice develop multiple liver tumors. Genes Dev.
25:795–800. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Varela AS and López Sáez JJ: Utility of
plasmatic levels of alpha-1-antiprotease (A1AP) as a cancer marker.
Cancer Lett. 89:15–21. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hidvegi T, Ewing M, Hale P, Dippold C,
Beckett C, Kemp C, Maurice N, Mukherjee A, Goldbach C, Watkins S,
et al: An autophagy-enhancing drug promotes degradation of mutant
α1-antitrypsin Z and reduces hepatic fibrosis. Science.
329:229–232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Xianfei X, Xiaoqiang C, Shunying Z and
Guolin Z: Chemical composition and antimicrobial activity of
essential oils of Chaenomeles speciosa from China. Food Chem.
100:1312–1315. 2007. View Article : Google Scholar
|
|
50
|
Nahrstedt A and Butterweck V: Biologically
active and other chemical constituents of the herb of Hypericum
perforatum L. Pharmacopsychiatry. 30(Suppl 2): 129–134. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Luan L, Wang G and Lin R: Studies on the
chemical constituents of extract with water from Forsythia
suspensa. Zhong Yao Cai. 33:220–221. 2010.(In Chinese). PubMed/NCBI
|
|
52
|
Yang YB, Yang Y, Li X, Yang Z, Wu ZJ,
Zheng YL and Sun LN: Studies on the chemical constituents of
Chaenomeles speciosa. Zhong Yao Cai. 32:1388–1390. 2009.(In
Chinese). PubMed/NCBI
|
|
53
|
Psahoulia FH, Moumtzi S, Roberts ML,
Sasazuki T, Shirasawa S and Pintzas A: Quercetin mediates
preferential degradation of oncogenic Ras and causes autophagy in
Ha-RAS-transformed human colon cells. Carcinogenesis. 28:1021–1031.
2007. View Article : Google Scholar
|
|
54
|
Isakson P, Bjørås M, Bøe SO and Simonsen
A: Autophagy contributes to therapy-induced degradation of the
PML/RARA oncoprotein. Blood. 116:2324–2331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hsueh YS, Yen CC, Shih NY, Chiang NJ, Li
CF and Chen LT: Autophagy is involved in endogenous and
NVP-AUY922-induced KIT degradation in gastrointestinal stromal
tumors. Autophagy. 9:220–233. 2013. View Article : Google Scholar :
|
